fashion -WSS

fashion

author：fashion 2025-09-28 05:04:48 - browse：9512

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Stories you might have missed in 2023: health, science, medicine

WSS

In shift, Texas to cover initial consult for Afghan baby's gene therapy

FDA early review: GLP

Lupron, used to halt puberty in children, may cause lasting health problems

JPM pitch from hospitals? Revenue streams outside of patient care

Gene therapy denied for Afghan refugee whose father aided U.S.

Hubble vs. James Webb telescope images: See the difference

entertainment

fashion

knowledge

In Memoriam: Notable people who died in 2023

Lupron, used to halt puberty in children, may cause lasting health problems

What does generative AI mean for health care? We asked experts

Dexcom's push to bring CGM to type 2 diabetes patients

Peter Hotez and the public health issue of online harassment

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

DIEP, the 'gold standard' of breast reconstruction, is under threat

Undocumented workers face uncertainty as immigration law takes effect in Florida

Duchenne breakthrough therapy leaves behind pioneering families

Allen Institute goes after foundational questions, CEO Costa says

focus

Merck to acquire Harpoon Therapeutics for $680 million

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Vertex cell therapy lets patients with type 1 diabetes stop insulin

How Robert F. Kennedy Jr. distorted vaccine science

Gene therapy denied for Afghan refugee whose father aided U.S.

Fauci's latest grilling in Congress: 9 hours, behind closed doors

entertainment

Wikipedia

hotspot

leisure time